Learn how ATTR-CM is treated with medications that slow down the condition's progression and other therapies that reduce symptoms and improve the quality of life.

The advanced heart failure market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical companies such as ...

With EA FC 26 on the horizon, EA Sports has confirmed all of the new gameplay features coming to the latest EA Sports FC ...

There is decreased risk of all-cause and CV mortality in patients with transthyretin amyloidosis with cardiomyopathy treated with vutrisiran.

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Alnylam (Nasdaq: ALNY) has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults ...

This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type ...

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

Irregular heartbeat affecting your health? Learn how to detect heart arrhythmia, what causes it, and which treatments can ...

It is hoped that identifying those most at risk of Transthyretin Amyloidosis Cardiomyopathy will lead to an earlier diagnosis ...

Medically reviewed by Jeffrey S. Lander, MD ATTR-CM is an acronym for the medical condition called transthyretin amyloid cardiomyopathy. There are two causes of ATTR-CM, an inherited gene mutation and ...

Town have completed the signing of Rennes midfielder Azor Matusiwa on a four-year deal. The clubs are understood to have ...